Market Cap$42.90B
P/E68.13x
PEG Ratio1.63
Div yield—
Beta1.16
WAT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)22.11%
Price vs S&P 500 (4W)4.40%
PEG Ratio1.63
VGM Score49.36
P/E Ratio (Annual)68.13x
WAT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $3.01 | $3.05 | +1.41%(+$0.04) | |
| Q1 2026 | $2.31 | $2.70 | +16.99%(+$0.39) | |
| Q4 2025 | $4.51 | $4.53 | +0.46%(+$0.02) | |
| Q3 2025 | $3.22 | $3.40 | +5.46%(+$0.18) | |
| Q2 2025 | $2.94 | $2.95 | +0.26%(+$0.01) |
WAT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.86
3.80
3.81
3.94
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
| ALMRAlamar Biosciences, Inc. Common Stock | — | A | B | — | — | — | — | $25.28 |
About Waters Corp
Waters manufactures analytical instruments including liquid chromatography, mass spectrometry, and thermal analysis systems. The company served biopharmaceutical (58%), industrial (31%), and academic/government (11%) customers in 2024. Waters has announced a merger with BD's life science and diagnostics business expected in early 2026, which will add diagnostics capabilities and expand its life sciences product portfolio.